Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $0.8 | ($1.7) | ($1.8) | ($1.6) | ($1.1) | ($0.9) | ($1.3) | ($2.5) | $7.9 | $4.2 | $3.4 | $6.2 | $8.6 | $11.3 | $21.3 | $19.4 | $32.7 | $76.4 | $40.5 | $37.1 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Regeneron Pharmaceuticals, Inc.'s last 12-month EPS is $43.2, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Regeneron Pharmaceuticals, Inc.'s EPS growth was 15.7%. The average annual EPS growth rates for Regeneron Pharmaceuticals, Inc. have been 4.7% over the past three years, 17.0% over the past five years.
Over the last year, Regeneron Pharmaceuticals, Inc.'s EPS growth was 15.7%, which is higher than industry growth of (0.2%). It indicates that Regeneron Pharmaceuticals, Inc.'s EPS growth is Good.